2-{[2-(3,3-dimethyl-ureido)-pyridin-4-ylmethyl]-amino}-6-fluoro-N-(2-methyl-2H-indazol-6-yl)-benzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-{[2-(3,3-dimethyl-ureido)-pyridin-4-ylmethyl]-amino}-6-fluoro-N-(2-methyl-2H-indazol-6-yl)-benzamide
• 英文别名: 2-[[2-(dimethylcarbamoylamino)pyridin-4-yl]methylamino]-6-fluoro-N-(2-methylindazol-6-yl)benzamide
• 化学式: C₂₄H₂₄FN₇O₂
• 分子量: 461.499
• InChiKey: BRLGDQYVDPRZKC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  34
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  104
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-[(2-bromo-pyridin-4-ylmethyl)-amino]-6-fluoro-N-(2-methyl-2H-indazol-6-yl)-benzamide 、 N,N-二甲基脲 在 tris(dibenzylideneacetone)dipalladium(0) chloroform complex caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 以40%的产率得到2-{[2-(3,3-dimethyl-ureido)-pyridin-4-ylmethyl]-amino}-6-fluoro-N-(2-methyl-2H-indazol-6-yl)-benzamide
  参考文献：
  名称：

  Anthranilamide pyridinureas as VEGF receptor kinase inhibitors

  摘要：

  本发明涉及一种新型的蒽酰胺吡啶脲作为VEGF受体激酶抑制剂，其制备和用作药物治疗由持续血管生成引起的疾病。

  公开号：

  EP1655295A1

文献信息

• SYNTHESIS OF ANTHRANILAMIDES
  申请人：SCHMEES Norbert

  公开号：US20080242866A1

  公开（公告）日：2008-10-02

  The present invention relates to a novel method of preparing anthranilamides of formula I: in which R 1 , R 2 , R 3 , A, E, Q, X, and W are defined in the claims, to a novel intermediate compound, and to the use of said novel intermediate compound for the preparation of said anthranilamides of formula I.

  本发明涉及一种制备公式I的新型方法：其中R1、R2、R3、A、E、Q、X和W在权利要求中定义，一种新型中间化合物，以及利用该新型中间化合物制备所述公式I的那些蒽酰胺的用途。
• Novel anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
  申请人：Bohlmann Rolf

  公开号：US20060116380A1

  公开（公告）日：2006-06-01

  The invention relates to novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis.

  本发明涉及一种新型的蒽酰胺吡啶脲作为VEGF受体激酶抑制剂，它们的制备和用作药物代理，用于预防或治疗由持续血管生成引起的疾病。
• Novel nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
  申请人：Bohlmann Rolf

  公开号：US20060160861A1

  公开（公告）日：2006-07-20

  The invention relates to novel nicotinamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis.

  本发明涉及一种新型烟酰胺吡啶脲作为VEGF受体激酶抑制剂，它们的制备方法以及作为预防或治疗由持续性血管生成引起的疾病的药物代理的用途。
• Anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
  申请人：Bayer Schering Pharma AG

  公开号：US07902229B2

  公开（公告）日：2011-03-08

  The invention relates to novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis.

  本发明涉及一种新型的蒽酰胺吡啶脲作为VEGF受体激酶抑制剂，其制备和用作预防或治疗由持续性血管生成引起的疾病的药物。
• NOVEL ANTHRANILAMIDE PYRIDINUREAS AS VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTOR KINASE INHIBITORS
  申请人：BOHLMANN Rolf

  公开号：US20110124680A1

  公开（公告）日：2011-05-26

  The invention relates to novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis.

  本发明涉及一种新型的蒽酰胺吡啶脲作为VEGF受体激酶抑制剂，其制备和用作预防或治疗由持续血管生成引起的疾病的药物。